Abstract:<p class="a-plus-plus">Vitiligo is an autoimmune disease of the skin characterized by epidermal melanocyte loss resulting in white patches, with an approximate prevalence of 0.5–2% worldwide. Several precipitating factors by chemical exposure and skin injury present commonly in patients with vitiligo. Although the diagnosis appears to be straightforward for the distinct clinical phenotype and specific histological features, vitiligo provides many challenges including chronicity, treatment resistance, frequent relapse, associated profound psychosocial effect, and negative impact on quality of life. Multiple mechanisms are involved in melanocyte disappearance, including genetics, environmental factors, and immune-mediated inflammation. Compelling evidence supports the melanocyte intrinsic abnormalities with poor adaptation to stressors leading to instability and release of danger signals, which will activate dendritic cells, natural killer cells, and innate lymphoid cells to initiate innate immunity, ultimately resulting in T-cell mediated adaptive immune response and melanocyte destruction. Importantly, the cross- talk between keratinocytes, melanocytes, and immune cells, such as interferon (IFN)-γ signaling pathway, builds inflammatory loops that give rise to the disease deterioration. Improved understanding of the immune pathogenesis of vitiligo has led to the development of new therapeutic options including Janus kinase (JAK) inhibitors targeting IFN-γ signaling pathways, which can effectively reverse depigmentation. Furthermore, definition of treatment goals and integration of comorbid diseases into vitiligo management have revolutionized the way vitiligo is treated. In this review, we highlight recent developments in vitiligo clinical aspects and immune pathogenesis. Our key objective is to raise awareness of the complexity of this disease, the potential of prospective therapy strategies, and the need for early and comprehensive management.</p>

Summarization on Experiences of Professor Wang Jusheng in Vitiligo Treatment

Discussion on Professor He Xiaohui's Experience in Treating Chronic Atrophic Gastritis

The Experience of Professor Xu Xian in Treating Eczema

The Treatment of Vitiligo with Liver and Kidney Deficiencies

Considerations on Ethics in the Process of Vitiligo Treatment

Clinical Eexperience of Professor FAN Yong-sheng on Proved Cases of Syndrome Differentiation and Treatment in Dermatogic Diseases

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

A summary of Professor JIA Chunsheng's clinical experience in treating cubital tunnel syndrome

Vitiligo: advances in pathophysiology research and treatment development

Professor Shi Yumin's Experience in Treating Childhood Asthma

Qiao Chengli's experiences in the treatment of nephritic syndrome with wenyang huazhuo therapy

Clinical experience of professor WANG Qi in treating hyperhidrosis based on the constitution factor

[Exploration of professor ZHANG Shan-chen's academic thoughts]

Advances in vitiligo: Update on therapeutic targets

Advances in the Research about Vitiligo Immunology

Vitiligo Treatment : A Review of Latest Treatment Researches

Effects of a Traditional Caraway Formulation on Experimental Models of Vitiligo and Mechanisms of Melanogenesis

Current traditional Chinese medicine treatments of psoriasis vulgaris

Professor Xia Xiang'S Clinical Experience in Treating Internal Disease

Bridging Molecular Mechanism and Clinical Practice in Vitiligo Treatment: An Updated Review

Understanding Vitiligo: Causes, Diagnosis, Promising Advances in Treatment and Management and the Impact on Mental Health